Generic Portal

Non-tumor ccaat/enhancer-binding protein delta potentiates tumor cell extravasation and pancreatic cancer metastasis formation

Duitman, J., Hartl, L., Roelofs, J. J. T. H., Bijlsma, M. F. & Arnold Spek, C., 1 Aug 2021, In: Biomolecules. 11, 8, 1079.

Research output: Contribution to journal › Article › Academic › peer-review

The recurring features of molecular subtypes in distinct gastrointestinal malignancies—A systematic review

Adam, R. S., Blomberg, I., ten Hoorn, S., Bijlsma, M. F. & Vermeulen, L., 1 Aug 2021, In: Critical reviews in oncology/hematology. 164, 103428.

Research output: Contribution to journal › Review article › Academic › peer-review

Adam9-responsive mesoporous silica nanoparticles for targeted drug delivery in pancreatic cancer

Slapak, E. J., Kong, L., Mandili, M. E., Nieuwland, R., Kros, A., Bijlsma, M. F. & Arnold Spek, C., 1 Jul 2021, In: Cancers. 13, 13, 3321.

Research output: Contribution to journal › Article › Academic › peer-review

Stem cells in the exocrine pancreas during homeostasis, injury, and cancer

Lodestijn, S. C., van Neerven, S. M., Vermeulen, L. & Bijlsma, M. F., 1 Jul 2021, In: Cancers. 13, 13, 3295.

Research output: Contribution to journal › Review article › Academic › peer-review

Apc-mutant cells act as supercompetitors in intestinal tumour initiation

van Neerven, S. M., de Groot, N. E., Nijman, L. E., Scicluna, B. P., van Driel, M. S., Lecca, M. C., Warmerdam, D. O., Kakkar, V., Moreno, L. F., Vieira Braga, F. A., Sanches, D. R., Ramesh, P., ten Hoorn, S., Aelvoet, A. S., van Boxel, M. F., Koens, L., Krawczyk, P. M., Koster, J., Dekker, E., Medema, J. P., & 5 othersWinton, D. J., Bijlsma, M. F., Morrissey, E., Léveillé, N. & Vermeulen, L., 17 Jun 2021, In: Nature. 594, 7863, p. 436-441 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction

Galeotti, A. A., Gentiluomo, M., Rizzato, C., Obazee, O., Neoptolemos, J. P., Pasquali, C., Nentwich, M., Cavestro, G. M., Pezzilli, R., Greenhalf, W., Holleczek, B., Schroeder, C., Schöttker, B., Ivanauskas, A., Ginocchi, L., Key, T. J., Hegyi, P., Archibugi, L., Darvasi, E., Basso, D., & 46 othersSperti, C., Bijlsma, M. F., Palmieri, O., Hlavac, V., Talar-Wojnarowska, R., Mohelnikova-Duchonova, B., Hackert, T., Vashist, Y., Strouhal, O., Van Laarhoven, H., Tavano, F., Lovecek, M., Dervenis, C., Izbéki, F., Padoan, A., Małecka-Panas, E., Maiello, E., Vanella, G., Capurso, G., Izbicki, J. R., Theodoropoulos, G. E., Jamroziak, K., Katzke, V., Kaaks, R., Mambrini, A., Papanikolaou, I. S., Szmola, R., Szentesi, A., Kupcinskas, J., Bursi, S., Costello, E., Boggi, U., Milanetto, A. C., Landi, S., Gazouli, M., Vodickova, L., Soucek, P., Gioffreda, D., Gemignani, F., Brenner, H., Strobel, O., Büchler, M., Vodicka, P., Paiella, S., Canzian, F. & Campa, D., 1 Jun 2021, In: Journal of medical genetics. 58, 6, p. 369-377 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase ii feasibility trial (PERFECT)

Van Den Ende, T., De Clercq, N. C., Van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Mohammad, N. H., Ruurda, J. P., Van Hillegersberg, R., Mook, S., Nieuwdorp, M., De Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., Van Grieken, N. C. T., Bijlsma, M. F., & 2 othersHulshof, M. C. C. M. & Van Laarhoven, H. W. M., Jun 2021, In: Clinical cancer research. 27, 12, p. 3351-3359 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

The case for a stratified application of targeted agents against pancreatic cancer

Bijlsma, M. F., 1 May 2021, In: EBioMedicine. 67, 103344.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox

Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Pereira, J. P. B., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G-J., Nieuwenhuijzen, G. A. P., Mohammad, N. H., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., Henegouwen, M. I. V. B. & van Laarhoven, H. W. M., 1 Feb 2021, In: Cancers. 13, 4, p. 1-15 15 p., 839.

Research output: Contribution to journal › Article › Academic › peer-review